Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. reported strong results for the quarter ended June 30, 2026, with revenue of $3.73 billion, up 5.8% year over year, and diluted EPS of $3.64 versus $2.84. Adjusted EPS rose to $4.99, and adjusted operating margin improved to 15.8%.
Diagnostics Laboratories and Biopharma Laboratory Services both delivered mid‑single‑digit revenue growth and higher adjusted operating margins. Biopharma Laboratory Services revenue was $836.2 million, up 6.5%, and backlog was $8.73 billion, with a trailing twelve‑month book‑to‑bill of 1.03.
Labcorp raised its 2026 outlook, guiding to enterprise revenue of $14,710–$14,827 million and adjusted EPS of $18.10–$18.55. During the quarter it invested $225.7 million in acquisitions, repurchased $353.8 million of stock, paid $58.7 million in dividends, retired $500.0 million of senior notes, and its board increased the remaining share repurchase authorization to $1.4 billion.
Labcorp Holdings Inc. reported that its Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on September 11, 2026 to stockholders of record at the close of business on August 28, 2026.
Labcorp describes itself as a global leader in innovative and comprehensive laboratory services, supporting doctors, hospitals, pharmaceutical companies, researchers, and patients. The company has nearly 71,000 employees, serves clients in approximately 100 countries, supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients worldwide.
Labcorp Holdings Inc. EVP and Chief Legal Officer Kathryn W. Kyle reported several equity transactions involving company stock. On July 1, 2026, she exercised 256 Restricted Stock Units, receiving the same number of common shares, while 73 shares were withheld to cover tax obligations. On July 2, 2026, she made an open-market sale of 92 common shares at $286.19 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds about 3,904.4574 common shares, and the filing notes an aggregate holding of 2,008 Restricted Stock Units.
Labcorp Holdings executive Bryan T. Vaughn reported an option-style vesting and a small open-market sale of company stock. On July 1, 2026, 327 Restricted Stock Units converted into the same number of Labcorp common shares, while 93 shares were withheld to cover tax obligations.
On July 2, 2026, Vaughn sold 234 common shares in an open-market transaction at $286.19 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 6,745.5702 Labcorp shares and 3,704 Restricted Stock Units in total.
Kathryn W. Kyle reported a sale of Common Stock. The filing shows a sale of 762 shares of Common Stock on 06/08/2026 for $201,084.18. The notice also lists 92 restricted shares tied to a Restricted Stock Vesting event with an effective date of 07/01/2026.
LH notice: an affiliate submitted a Form 144 reporting a proposed sale of 7,138 shares of Common stock, listed with a date of 07/01/2026 and described as arising from a Stock Option Exercise with cash proceeds. The filing also records a prior sale of 6,238 shares on 05/06/2026 for $1,601,648.81.
Labcorp Holdings Inc. will release its financial results for the second quarter of 2026 before the market opens on July 30, 2026. The company will host a webcast at 9:00 a.m. ET the same day to discuss the results.
The earnings press release and detailed financial information will be posted in the “News & Events” section of Labcorp’s investor relations website, where investors can also access the live webcast link. A replay of the webcast will be available on the same site about two hours after the live event and will remain accessible for one year.
LABCORP HOLDINGS INC. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported an open-market sale of Common Stock. On June 8, 2026, she sold 762 shares at $263.89 per share in a transaction made under a pre-arranged Rule 10b5-1 trading plan. After this sale, she directly owns about 3,813.4574 shares of Labcorp common stock.
LH submitted a Form 144 notice listing proposed sales of Common Stock related to recent restricted stock vesting events. The filing itemizes small vested lots (59, 59, 77, 567 shares) with transaction dates in February–March 2026 and identifies a broker Fidelity Brokerage Services LLC.